Tudor Investment Corp
NWBO

Tudor Investment Corp’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Tudor Investment Corp’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-31,660
Closed -$11K – 1682
2016
Q4 		$11K Hold
31,660
– – ﹤0.01% 1353
2016
Q3 		$17K Hold
31,660
– – ﹤0.01% 1394
2016
Q2 		$18K Hold
31,660
– – ﹤0.01% 1572
2016
Q1 		$46K Buy
31,660
+600
+2% +$1.18K ﹤0.01% 1657
2015
Q4 		$99K Buy
31,060
+3,724
+14% +$17.9K ﹤0.01% 1539
2015
Q3 		$171K Buy
27,336
+7,068
+35% +$66.1K 0.01% 1370
2015
Q2 		$201K Sell
20,268
-2,245
-10% -$19.7K 0.01% 1335
2015
Q1 		$166K Buy
+22,513
New +$152K 0.01% 1326

Other funds holding NWBO

MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
WPP
Whalerock Point Partners Providence, Rhode Island $518M AUM 25.26% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Tudor Investment Corp's NWBO Position: Q1 2017 in Review

Tudor Investment Corp sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2017, closing a stake of 31,660 shares — an estimated $11K sold.

Tudor Investment Corp first reported a position in NWBO in Q1 2015 and held it in 8 quarters. The position peaked at $201K in Q2 2015. 4 funds tracked by Wall St. Rank hold NWBO as of Q1 2017.

  • Tudor Investment Corp reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2017 after selling out during the quarter.
  • Tudor Investment Corp sold 31,660 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2017, an estimated $11K.
  • Tudor Investment Corp first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2015 and held it in 8 quarters.
  • Tudor Investment Corp's Northwest Biotherapeutics, Inc. Common stock position peaked at $201K in Q2 2015.
  • 4 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2017.

Based on Tudor Investment Corp's 13F filing for Q1 2017, filed 15 May 2017.